BACKGROUND: Type II diabetes and obesity are major health problems worldwide and aboriginal peoples are particularly at risk. To address this problem in Canadian native populations who find modern pharmaceuticals culturally inappropriate, our team is testing the traditional pharmacopeia of the James Bay Cree for anti-diabetic and anti-obesity activities. More specifically, the aim of the present study was to define the effects of traditional plants on intestinal glucose absorption, an under-appreciated anti-hyperglycaemic and anti-obesity activity. METHODS: Crude ethanol extracts of 17 Boreal forest medicinal plants were tested in vitro using the Caco-2 human enterocytic cell line and in vivo using an oral glucose tolerance test. RESULTS: Thirteen of seventeen extracts were observed to significantly inhibit uptake when administered simultaneously with (3)H-deoxyglucose. Inhibition was dose-dependent and, in a few cases, even surpassed that induced by a combination of the positive controls. To validate these effects in vivo, four plant extracts were administered by intragastric gavage at 250 mg/kg to normal rats simultaneously with a 3g/kg bolus of glucose. This resulted in a decrease in peak glycaemia by approximately 40% for two of them. Similarly, only 2 extracts reduced glucose transport after long term incubation and this could be related to reductions in the expression of SGLT-1 or GLUT-2 proteins. CONCLUSIONS: These findings indicate that competitive inhibition of intestinal glucose uptake can be achieved by crude extracts of medicinal plants. Such extracts could be taken with meals to control postprandial glycaemia and reduce caloric intake in high risk populations that are positively inclined towards traditional medicine.
BACKGROUND:Type II diabetes and obesity are major health problems worldwide and aboriginal peoples are particularly at risk. To address this problem in Canadian native populations who find modern pharmaceuticals culturally inappropriate, our team is testing the traditional pharmacopeia of the James Bay Cree for anti-diabetic and anti-obesity activities. More specifically, the aim of the present study was to define the effects of traditional plants on intestinal glucose absorption, an under-appreciated anti-hyperglycaemic and anti-obesity activity. METHODS: Crude ethanol extracts of 17 Boreal forest medicinal plants were tested in vitro using the Caco-2 human enterocytic cell line and in vivo using an oral glucose tolerance test. RESULTS: Thirteen of seventeen extracts were observed to significantly inhibit uptake when administered simultaneously with (3)H-deoxyglucose. Inhibition was dose-dependent and, in a few cases, even surpassed that induced by a combination of the positive controls. To validate these effects in vivo, four plant extracts were administered by intragastric gavage at 250 mg/kg to normal rats simultaneously with a 3g/kg bolus of glucose. This resulted in a decrease in peak glycaemia by approximately 40% for two of them. Similarly, only 2 extracts reduced glucose transport after long term incubation and this could be related to reductions in the expression of SGLT-1 or GLUT-2 proteins. CONCLUSIONS: These findings indicate that competitive inhibition of intestinal glucose uptake can be achieved by crude extracts of medicinal plants. Such extracts could be taken with meals to control postprandial glycaemia and reduce caloric intake in high risk populations that are positively inclined towards traditional medicine.
Authors: Pierre S Haddad; Lina Musallam; Louis C Martineau; Cory Harris; Louis Lavoie; John T Arnason; Brian Foster; Steffany Bennett; Timothy Johns; Alain Cuerrier; Emma Coon Come; Rene Coon Come; Josephine Diamond; Louise Etapp; Charlie Etapp; Jimmy George; Charlotte Husky Swallow; Johnny Husky Swallow; Mary Jolly; Andrew Kawapit; Eliza Mamianskum; John Petagumskum; Smalley Petawabano; Laurie Petawabano; Alex Weistche; Alaa Badawi Journal: Evid Based Complement Alternat Med Date: 2011-12-20 Impact factor: 2.629
Authors: Despina Harbilas; Diane Vallerand; Antoine Brault; Ammar Saleem; John T Arnason; Lina Musallam; Pierre S Haddad Journal: Evid Based Complement Alternat Med Date: 2012-07-19 Impact factor: 2.629